BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22843211)

  • 1. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.
    Asahina H; Nokihara H; Yamamoto N; Yamada Y; Tamura Y; Honda K; Seki Y; Tanabe Y; Shimada H; Shi X; Tamura T
    Invest New Drugs; 2013 Jun; 31(3):677-84. PubMed ID: 22843211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.
    Naing A; Aghajanian C; Raymond E; Olmos D; Schwartz G; Oelmann E; Grinsted L; Burke W; Taylor R; Kaye S; Kurzrock R; Banerji U
    Br J Cancer; 2012 Sep; 107(7):1093-9. PubMed ID: 22935583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
    Kondo S; Tajimi M; Funai T; Inoue K; Asou H; Ranka VK; Wacheck V; Doi T
    Invest New Drugs; 2020 Dec; 38(6):1836-1845. PubMed ID: 32578154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
    Li Q; Song XM; Ji YY; Jiang H; Xu LG
    Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
    Ando Y; Inada-Inoue M; Mitsuma A; Yoshino T; Ohtsu A; Suenaga N; Sato M; Kakizume T; Robson M; Quadt C; Doi T
    Cancer Sci; 2014 Mar; 105(3):347-53. PubMed ID: 24405565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
    English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
    Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors.
    Wang J; Gui L; Mu Y; Wang J; Chi Y; Liu Z; Li Q; Xu B
    BMC Cancer; 2023 Dec; 23(1):1200. PubMed ID: 38057772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of orally administered
    MacDonald A; Scarfe G; Magirr D; Sarvotham T; Charlton J; Brugger W; Dean E
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):787-795. PubMed ID: 30758651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.
    Lewis NL; Lewis LD; Eder JP; Reddy NJ; Guo F; Pierce KJ; Olszanski AJ; Cohen RB
    J Clin Oncol; 2009 Nov; 27(31):5262-9. PubMed ID: 19738123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
    Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
    Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
    [No Abstract]   [Full Text] [Related]  

  • 14. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
    Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
    Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
    Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
    Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.
    Koyama T; Shimizu T; Iwasa S; Fujiwara Y; Kondo S; Kitano S; Yonemori K; Shimomura A; Iizumi S; Sasaki T; Furuse J; Yamamoto N
    Cancer Sci; 2020 Feb; 111(2):571-579. PubMed ID: 31797489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
    Pike KG; Malagu K; Hummersone MG; Menear KA; Duggan HM; Gomez S; Martin NM; Ruston L; Pass SL; Pass M
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1212-6. PubMed ID: 23375793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
    Fujisaka Y; Onozawa Y; Kurata T; Yasui H; Goto I; Yamazaki K; Machida N; Watanabe J; Shimada H; Shi X; Boku N
    Invest New Drugs; 2013 Feb; 31(1):108-14. PubMed ID: 22415795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.